Upcoming events – Karyopharm's myeloma expansion and Pfizer's biz dev nous
Karyopharm hopes to move Xpovio earlier in the multiple myeloma treatment sequence, and data are due for Akcea/Ionis’s triglyceride regulator, for which Pfizer paid a…
Upcoming events – TG's long-awaited outcome and Insmed's mid-stage lung data
After making investors wait more than a year, TG Therapeutics is gearing up to release results of its lead leukaemia combo, while Insmed hopes to succeed in a very tricky…
Upcoming events – Axsome’s depression data and Lilly’s IL-10 in lung cancer
Axsome hopes to end 2019 on a high with its depression drug AXS-05 while Lilly’s pegilodecakin is unlikely to redeem itself in lung cancer.
SABCS 2019 – Astrazeneca and Daiichi join the Her2 resistance
New data confirms that trastuzumab deruxtecan has an exciting destiny, but the antibody-drug conjugate’s impressive efficacy in late-stage breast cancer comes at a price.
Ash 2019 – Regeneron takes the bispecific baton and runs
Regeneron and Xencor add to the growing evidence backing bispecifics in certain lymphomas, a space that looks set to become fiercely competitive.
Upcoming events – Gilead’s Nash refocus and an early chance for Ionis and Roche
Data from Gilead's Atlas combination trial in Nash could point to a way forward, while Roche and Ionis are hoping to confirm earlier signals seen with a…
Astellas spends $3bn on a bold move into gene therapy
The Japanese group has seen potential in Audentes' manufacturing capabilities as well as its pipeline.
Upcoming events – Kalvista aims for acuity and a me-too from Sanofi approaches
As Kalvista hopes to attract Merck & Co, Sanofi plays catch-up with Genmab.
The first test of Spectrum’s shift
By the end of December poziotinib will deliver results that could justify the strategic refocusing Spectrum undertook this year.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.